The present disclosure relates to the field of pharmacology, and in particular, to a preparation method of high-purity total ginkgo flavonol glycoside. The preparation method of high-purity total ginkgo flavonol glycoside includes: (1) mixing Ginkgo biloba extract powder and a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant; (2) subjecting the supernatant to separation with an acid-polar coupled macroporous resin column and to purification with a polyamide column, to obtain high-purity total ginkgo flavonol glycoside. The purity of the total ginkgo flavonol glycoside prepared by the preparation method of high-purity total ginkgo flavonol glycoside according to the present disclosure is ≥90%, and has good clinical application prospects; the preparation process does not require organic reagents such as petroleum ether and ethyl acetate, which is environmentally friendly; the transfer rate of the total flavonol glycoside is high.

The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.

The purpose of the present invention is to provide a novel compound which has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare that are causative bacteria of MAC infection and which is different in backbone structure from known drugs for treatment of MAC infection. One aspect of the present invention relates to a compound of Formula (I) [where R.sup.1 has the same meaning as described in the specification and claims] or a salt thereof, or a solvate thereof. Another aspect of the present invention relates to a method for producing the compound of Formula (I) or a salt thereof, or a solvate thereof, and a therapeutic agent for Mycobacterium avium complex infection (MAC infection), which comprises the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient. ##STR00001##

The purpose of the present invention is to provide a novel compound which has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare that are causative bacteria of MAC infection and which is different in backbone structure from known drugs for treatment of MAC infection. One aspect of the present invention relates to a compound of Formula (I) [where R.sup.1 has the same meaning as described in the specification and claims] or a salt thereof, or a solvate thereof. Another aspect of the present invention relates to a method for producing the compound of Formula (I) or a salt thereof, or a solvate thereof, and a therapeutic agent for Mycobacterium avium complex infection (MAC infection), which comprises the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient. ##STR00001##

The present invention relates to a use of a compound comprising a multivalent sialyloligosaccharide residue, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a composition comprising the same as an active ingredient for preventing or treating viral infectious diseases. The present invention shows high hemagglutination inhibitory activity and virus neutralizing activity so as to have excellent antiviral activity, thereby being effectively usable as a composition for preventing or treating viral infectious diseases.

The present invention relates to a use of a compound comprising a multivalent sialyloligosaccharide residue, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a composition comprising the same as an active ingredient for preventing or treating viral infectious diseases. The present invention shows high hemagglutination inhibitory activity and virus neutralizing activity so as to have excellent antiviral activity, thereby being effectively usable as a composition for preventing or treating viral infectious diseases.

Analogues of oleuropein and oleacein and pharmaceutically acceptable salts thereof and processes for the preparation of these compounds are disclosed. The invention further relates to use of oleuropein and oleacein analogues for the treatment of inflammatory disorders, cardiometabolic disorders, and cancer.

Analogues of oleuropein and oleacein and pharmaceutically acceptable salts thereof and processes for the preparation of these compounds are disclosed. The invention further relates to use of oleuropein and oleacein analogues for the treatment of inflammatory disorders, cardiometabolic disorders, and cancer.

This invention is directed to compositions comprising dibenzo-alpha-pyrones (DBPs, Urolithins) and DBP glycosides, and methods of improving the immune system, providing immuno-protection, and/or treating immunosuppression in a subject with the compositions. The compounds 3-OH-DBP (Urolithin B), 3,8-(OH).sub.2-DBP (Urolithin A), and their glycosides are discussed.

This invention is directed to compositions comprising dibenzo-alpha-pyrones (DBPs, Urolithins) and DBP glycosides, and methods of improving the immune system, providing immuno-protection, and/or treating immunosuppression in a subject with the compositions. The compounds 3-OH-DBP (Urolithin B), 3,8-(OH).sub.2-DBP (Urolithin A), and their glycosides are discussed.